Prognostic Value of LGE-CMR in HCM

JACC: Cardiovascular Imaging - Tập 9 Số 12 - Trang 1392-1402 - 2016
Zhen Weng1, Jialu Yao2, Raymond H. Chan3, Jun He1, Xiangjun Yang2, Yafeng Zhou4, Yang He5
1Cyrus Tang Hematology Center and Ministry of Education Engineering Center of Hematological Disease, the First Affiliated Hospital, and the Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
2Department of Cardiology, The First Affiliated Hospital of Soochow University, Suzhou, China
3Division of Cardiology, Peter Munk Cardiac Center, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada
4Department of Cardiology, the First Affiliated Hospital of Soochow University, Suzhou, China. Electronic address: [email protected].
5Cyrus Tang Hematology Center and Ministry of Education Engineering Center of Hematological Disease, the First Affiliated Hospital, and the Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China. Electronic address: [email protected].

Tóm tắt

Từ khóa


Tài liệu tham khảo

Klarich, 2013, Risk of death in long-term follow-up of patients with apical hypertrophic cardiomyopathy, Am J Cardiol, 111, 1784, 10.1016/j.amjcard.2013.02.040

Semsarian, 2015, New perspectives on the prevalence of hypertrophic cardiomyopathy, J Am Coll Cardiol, 65, 1249, 10.1016/j.jacc.2015.01.019

Maron, 2013, Hypertrophic cardiomyopathy, Lancet, 381, 242, 10.1016/S0140-6736(12)60397-3

Maron, 2007, Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy, JAMA, 298, 405, 10.1001/jama.298.4.405

Maron, 2013, Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy, J Am Coll Cardiol, 61, 1527, 10.1016/j.jacc.2013.01.037

Maron, 2009, Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance, J Am Coll Cardiol, 54, 220, 10.1016/j.jacc.2009.05.006

Pennell, 2010, Cardiovascular magnetic resonance, Circulation, 121, 692, 10.1161/CIRCULATIONAHA.108.811547

Reichek, 2008, Hypertrophic cardiomyopathy: cardiac magnetic resonance imaging changes the paradigm, J Am Coll Cardiol, 52, 567, 10.1016/j.jacc.2008.05.014

Maron, 2012, Clinical utility of cardiovascular magnetic resonance in hypertrophic cardiomyopathy, J Cardiovasc Magnet Reson, 14, 13, 10.1186/1532-429X-14-13

Green, 2012, Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy, J Am Coll Cardiol Img, 5, 370, 10.1016/j.jcmg.2011.11.021

Chan, 2014, Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy, Circulation, 130, 484, 10.1161/CIRCULATIONAHA.113.007094

Hen, 2014, Prognostic value of late gadolinium enhancement on cardiac magnetic resonance imaging in Japanese hypertrophic cardiomyopathy patients, Circ J, 78, 929, 10.1253/circj.CJ-13-0979

Ismail, 2014, Role of late gadolinium enhancement cardiovascular magnetic resonance in the risk stratification of hypertrophic cardiomyopathy, Heart, 100, 1851, 10.1136/heartjnl-2013-305471

Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed July 1, 2016.

Egger, 1997, Bias in meta-analysis detected by a simple, graphical test, BMJ, 315, 629, 10.1136/bmj.315.7109.629

Moher, 2009, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, PLoS Med, 6, e1000097, 10.1371/journal.pmed.1000097

Maron, 2008, Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy, Circ Heart Fail, 1, 184, 10.1161/CIRCHEARTFAILURE.108.768119

O'Hanlon, 2010, Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy, J Am Coll Cardiol, 56, 867, 10.1016/j.jacc.2010.05.010

Bruder, 2010, Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy, J Am Coll Cardiol, 56, 875, 10.1016/j.jacc.2010.05.007

Rubinshtein, 2010, Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy, Circ Heart Fail, 3, 51, 10.1161/CIRCHEARTFAILURE.109.854026

Briasoulis, 2015, Myocardial fibrosis on cardiac magnetic resonance and cardiac outcomes in hypertrophic cardiomyopathy: a meta-analysis, Heart, 101, 1406, 10.1136/heartjnl-2015-307682

Elliott, 2014, 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC), Eur Heart J, 35, 2733, 10.1093/eurheartj/ehu284

Wagner, 2009, Current variables, definitions and endpoints of the European cardiovascular magnetic resonance registry, J Cardiovasc Magn Res, 11, 43, 10.1186/1532-429X-11-43

Kuribayashi, 1992, Myocardial disarray at junction of ventricular septum and left and right ventricular free walls in hypertrophic cardiomyopathy, Am J Cardiol, 70, 1333, 10.1016/0002-9149(92)90771-P

Chan, 2015, Significance of late gadolinium enhancement at right ventricular attachment to ventricular septum in patients with hypertrophic cardiomyopathy, Am J Cardiol, 116, 436, 10.1016/j.amjcard.2015.04.060

Thông tin
Thông tin xuất bản

JACC: Cardiovascular Imaging

Tập 9 Số 12

1392-1402

Thông tin tác giả